BioFocus and Argenta Announce Drug Discovery Collaboration with AstraZeneca in Respiratory and Inflammatory Disease

15-Mar-2012 - Sweden

Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases.

Under the terms of the collaboration, each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta, and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta.

Financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances